Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

548
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
548
Analgesia and Pain Management01:25

Analgesia and Pain Management

980
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
980
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

495
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
495
Drug Therapy01:28

Drug Therapy

123
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
123
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

2.6K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.6K
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

832
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
832

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moderators of the impact of e-cigarette provision on smoking cessation: secondary analyses from a large naturalistic randomized clinical trial in the US.

Addictive behaviors·2026
Same author

Cultivating the Field of Rural Health Research: The Case for Rural Health Research Competencies.

The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association·2026
Same author

The dual use dilemma: Is it better to have tried and failed to quit smoking with e-cigarettes or to have never tried e-cigarettes at all?

Preventive medicine·2026
Same author

A recommendation to include support for perinatal smoking-cessation treatment in the SAMHSA advisory on contingency management.

Preventive medicine·2026
Same author

Treating those not ready to quit smoking: Doing harm while trying to help?

Addictive behaviors·2026
Same author

Utilizing Quantitative MRI for Morphological Assessment of Articular Cartilage Thickness in the Tibiofemoral Joint.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2026

Related Experiment Video

Updated: Oct 25, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.3K

Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and

Hypatia A Bolívar1,2, Elias M Klemperer1,2, Sulamunn R M Coleman1,2

  • 1Vermont Center on Behavior and Health, University of Vermont, Burlington.

JAMA Psychiatry
|August 4, 2021
PubMed
Summary

Contingency management significantly improves outcomes for medication treatment for opioid use disorder (MOUD) patients with comorbid stimulant use and other behavioral health issues. This behavioral intervention shows medium to large effect sizes for abstinence and adherence.

More Related Videos

A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

7.6K
Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.4K

Related Experiment Videos

Last Updated: Oct 25, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.3K
A Conflict Model of Reward-seeking Behavior in Male Rats
06:11

A Conflict Model of Reward-seeking Behavior in Male Rats

Published on: February 20, 2019

7.6K
Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.4K

Area of Science:

  • Behavioral Science
  • Addiction Medicine
  • Public Health

Background:

  • Medication treatment for opioid use disorder (MOUD) is effective but often hindered by co-occurring stimulant use and behavioral health problems.
  • Addressing these comorbidities is crucial for improving MOUD efficacy.

Purpose of the Study:

  • To evaluate the association between contingency management and end-of-treatment outcomes for individuals with MOUD and comorbid behavioral health issues.
  • To synthesize evidence on the effectiveness of contingency management in managing stimulant use, polysubstance use, illicit opioid use, smoking, therapy attendance, and medication adherence.

Main Methods:

  • A systematic literature search was conducted across major databases (PubMed, Cochrane CENTRAL, Web of Science) for studies published up to May 5, 2020.
  • Prospective experimental studies of monetary-based contingency management in MOUD participants were included.
  • Data were extracted and analyzed using random-effects meta-analysis following PRISMA guidelines.

Main Results:

  • Contingency management demonstrated positive associations with all six clinical problems examined.
  • Medium to large effect sizes were observed for stimulant use (Cohen d=0.70), cigarette smoking (Cohen d=0.78), illicit opioid use (Cohen d=0.58), and medication adherence (Cohen d=0.75).
  • Small to medium effect sizes were found for polysubstance use (Cohen d=0.46) and therapy attendance (Cohen d=0.43).

Conclusions:

  • Contingency management is an effective intervention for improving outcomes in patients receiving MOUD, particularly those with comorbid psychomotor stimulant misuse.
  • Evidence supports integrating contingency management into community-based MOUD services to address critical clinical challenges.
  • Policy changes are recommended to facilitate the widespread adoption of contingency management in MOUD treatment programs.